NYSE:CRY CryoLife (CRY) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free CRY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$17.19▼$21.7252-Week Range N/AVolume7,792 shsAverage Volume198,221 shsMarket Capitalization$703.22 millionP/E Ratio596.20Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get CryoLife alerts: Email Address Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About CryoLife Stock (NYSE:CRY)CryoLife, Inc. engages in the manufacture, process and distribution of medical devices and implantable human tissues. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue products, aortic stents and stent grafts, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment focuses on revenues from preservation of cardiac and vascular implantable human tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.Read More Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. CRY Stock News HeadlinesMarch 9, 2024 | investing.comBraskem SA Class A (BAK)February 16, 2024 | markets.businessinsider.comArtivion Secures Buy Rating: Strong Financials and Growth Trajectory Propel Price Target IncreaseMarch 19, 2024 | Behind the Markets (Ad)BlackRock Bets Big on Tiny BiotechAn undervalued biotech firm is on the verge of a major discovery - That has the potential to treat Alzheimer's, Parkinson's and Dementia. BlackRock is so confident in this firm, they've invested $298 million.February 14, 2024 | markets.businessinsider.comCryoLife earnings: here's what to expectFebruary 6, 2024 | finance.yahoo.comHemostats Market revenue to exceed USD 5000 Million by 2033, says Research NesterJanuary 31, 2024 | markets.businessinsider.comBuy Rating on Artivion’s Stock Backed by Strong PERSEVERE Study Results and Market PotentialJanuary 15, 2024 | finance.yahoo.comGlobal Cord Blood & Tissue Banking Industry Report Market Size, Segmentation, & Forecasts, 2024January 10, 2024 | finance.yahoo.comQ3 2024 Park Aerospace Corp Earnings CallMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.December 28, 2023 | seekingalpha.comArtivion Stock: A First AssessmentDecember 19, 2023 | finance.yahoo.comPediatric Heart Valve Repair and Replacement Market to Witness 2.7% CAGR, Reaching US$ 4,490.5 Million by 2034 | Future Market Insights, Inc.November 21, 2023 | markets.businessinsider.comWhy Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving PremarketNovember 1, 2023 | benzinga.comBone Cement Market Size, Growth & Statistical Report from 2023 to 2030October 19, 2023 | finance.yahoo.comAortic Stent Grafts Market to Surpass 3.01 Billion by 2030 Drives Due to Medical AdvancementsOctober 3, 2023 | finance.yahoo.comGlobal Aortic Stents Grafts Market to Record a CAGR of 5% and Reach US$ 4.2 billion by 2033 | Future Market Insights, Inc.September 14, 2023 | benzinga.comHeart Valve Devices Market to be Worth US$ 37.5 Billion by 2033 | Fact.MR ReportAugust 25, 2023 | finance.yahoo.comCardiac Sutures Global Market Report 2023August 5, 2023 | msn.comNeedham Reiterates Artivion (AORT) Buy RecommendationJuly 4, 2023 | finance.yahoo.comBiosurgery Global Market Report 2023June 9, 2023 | finance.yahoo.comDermatology Lasers Global Market Report 2023May 21, 2023 | uk.finance.yahoo.comCryoLife, Inc. (CYL.F)May 17, 2023 | finance.yahoo.comLaser Therapy Global Market Report 2023: Increasing Demand from Non-invasive Laser Surgeries Drives GrowthMay 17, 2023 | marketwatch.comRegenerative Medicine Market (2023-2030): Research Report, Growth, Trends and Competitive AnalysisMay 17, 2023 | marketwatch.comGlobal Tissue Level Implant Market to Witness Significant Growth Due to Increasing Adoption Forecast 2023-2030May 17, 2023 | marketwatch.comGlobal Hemostatic Gel Market [2023-2030] | Growing at a CAGR 5.2% (Expected to Reach 1356.5)May 16, 2023 | marketwatch.comGlobal Organ and Tissue Transplantation and Alternative Market Size 2023-2031 Business Strategies by Absolute Reports | with [94 Pages]May 16, 2023 | marketwatch.comBiomaterial Implants Market Current Status 2023: Regional Growth ProspectsSee More Headlines Receive CRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CryoLife and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & Medical Instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:CRY CUSIP22890310 CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,200Year Founded1984Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio596.20 Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,680,000.00 Net Margins0.63% Pretax Margin0.41% Return on Equity4.24% Return on Assets1.63% Debt Debt-to-Equity Ratio0.99 Current Ratio4.21 Quick Ratio2.93 Sales & Book Value Annual Sales$253.23 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow23.30 Book Value$8.46 per share Price / BookN/AMiscellaneous Outstanding Shares39,330,000Free Float37,560,000Market Cap$703.22 million OptionableOptionable Beta1.53 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesJames Patrick MackinChairman, President & Chief Executive OfficerDavid Ashley LeeChief Operating & Financial Officer, Executive VPScott B. CappsVice President-Clinical ResearchFranz Peter BartholdVice President-Research & DevelopmentMarshall S. StantonChief Medical Officer & SVP-Clinical ResearchKey CompetitorsOrthofix MedicalNASDAQ:OFIXSurmodicsNASDAQ:SRDXAccurayNASDAQ:ARAYAngioDynamicsNASDAQ:ANGOAtriCureNASDAQ:ATRCView All Competitors CRY Stock Analysis - Frequently Asked Questions How were CryoLife's earnings last quarter? CryoLife, Inc. (NYSE:CRY) posted its earnings results on Thursday, November, 4th. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of $0.04 by $0.22. The medical equipment provider had revenue of $72.21 million for the quarter, compared to the consensus estimate of $72.90 million. CryoLife had a trailing twelve-month return on equity of 4.24% and a net margin of 0.63%. During the same quarter in the prior year, the business earned $0.13 earnings per share. What is J. Patrick Mackin's approval rating as CryoLife's CEO? 53 employees have rated CryoLife Chief Executive Officer J. Patrick Mackin on Glassdoor.com. J. Patrick Mackin has an approval rating of 81% among the company's employees. What other stocks do shareholders of CryoLife own? Based on aggregate information from My MarketBeat watchlists, some companies that other CryoLife investors own include Energy Transfer (ET), AT&T (T), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Enterprise Products Partners (EPD), Gilead Sciences (GILD), Netflix (NFLX), Zoetis (ZTS), Ares Capital (ARCC) and Edwards Lifesciences (EW). Does CryoLife have any subsidiaries? The following companies are subsidiares of CryoLife: AuraZyme Pharmaceuticals Inc., Cardiogenesis Corporation, CryoLife Asia Pacific PTE. Ltd., CryoLife Canada Inc., CryoLife Europa Ltd., CryoLife France SAS., CryoLife Germany HoldCo GmbH, CryoLife Germany TopCo GmbH, CryoLife International Inc., Hemosphere, JOTEC AG, JOTEC Cardiovascular S.L., JOTEC Polska Sp. z.o.o, JOTEC Sales GmbH, JOTEC UK Ltd., JOTEC do Brasil, JOTEC s.r.l., Jolly Buyer Acquisition GmbH, Jotec, On-X Life Technologies Holdings Inc., On-X Life Technologies Inc., and Valve Special Purpose Co. LLC.Read More This page (NYSE:CRY) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoLife, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.